|
US5833975A
(en)
*
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
|
AT399656B
(de)
*
|
1993-03-19 |
1995-06-26 |
Boehringer Ingelheim Int |
Verfahren zur herstellung von krebsvakzinen
|
|
US6093700A
(en)
*
|
1995-05-11 |
2000-07-25 |
Thomas Jefferson University |
Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
|
|
AU688606B2
(en)
*
|
1994-10-03 |
1998-03-12 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
|
|
US6045802A
(en)
*
|
1994-10-03 |
2000-04-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
|
|
US5612030A
(en)
|
1995-01-17 |
1997-03-18 |
University Of Kentucky Research Foundation |
Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
|
|
US5935821A
(en)
*
|
1995-01-17 |
1999-08-10 |
Board Of Trustees Of The University Of Kentucky |
Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
|
|
US5977316A
(en)
*
|
1995-01-17 |
1999-11-02 |
The Board Of Trustees Of The University Of Kentucky |
Monoclonal antibody 1A7 and related polypeptides
|
|
US6001349A
(en)
*
|
1995-02-22 |
1999-12-14 |
Therion Biologics Corporation |
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
|
|
DK0811073T3
(da)
*
|
1995-02-24 |
2007-05-21 |
Univ Pennsylvania |
Avendelse af immunmodulatorer til fremstilling af medikamenter til inhibering af immunresponser mod co-administrerede rekombinanter
|
|
US6372208B1
(en)
|
1999-09-28 |
2002-04-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
|
US6251957B1
(en)
|
1995-02-24 |
2001-06-26 |
Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant virus
|
|
US5872154A
(en)
*
|
1995-02-24 |
1999-02-16 |
The Trustees Of The University Of Pennsylvania |
Method of reducing an immune response to a recombinant adenovirus
|
|
US5480640A
(en)
*
|
1995-05-02 |
1996-01-02 |
Schering Corporation |
Alpha interferon for treating prostate cancer
|
|
US6165460A
(en)
*
|
1995-07-10 |
2000-12-26 |
Therion Biologics Corporation |
Generation of immune responses to prostate-specific antigen (PSA)
|
|
AU731860B2
(en)
*
|
1996-07-25 |
2001-04-05 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Recombinant pox virus for immunization against tumor-associated antigens
|
|
WO1998029556A1
(en)
*
|
1996-12-31 |
1998-07-09 |
The Wistar Institute |
Recombinant adenoviral vector expressing antigens associated with colorectal tumors
|
|
DE19716892C1
(de)
*
|
1997-04-22 |
1998-09-03 |
Gsf Forschungszentrum Umwelt |
Expression von Immunglobulin-Zytokin-Fusionsproteinen in malignen B-Zellen
|
|
US6120806A
(en)
*
|
1997-06-25 |
2000-09-19 |
Whitmire; David R. |
Oral formulations for controlled release of alcohol deterrents
|
|
DE69840524D1
(de)
*
|
1997-08-13 |
2009-03-19 |
Uab Research Foundation |
Impfung durch topische verwendung genetischer vektoren
|
|
US6756038B1
(en)
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
|
ES2217585T3
(es)
*
|
1997-10-10 |
2004-11-01 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Peptidos agonistas y antagonistas del antigeno carcino-embrionario (cea).
|
|
US6355244B1
(en)
|
1997-11-17 |
2002-03-12 |
University Of Kentucky Research Foundation |
Methods and compositions for the treatment of psoriasis
|
|
US6506385B1
(en)
|
1998-04-17 |
2003-01-14 |
Embrex, Inc. |
Live vaccines and methods of treatment therewith
|
|
US7148035B1
(en)
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
|
US6896881B1
(en)
*
|
1999-09-24 |
2005-05-24 |
Mayo Foundation For Medical Education And Research |
Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
|
|
ATE391726T1
(de)
|
1999-10-22 |
2008-04-15 |
Sanofi Pasteur Ltd |
Modifiziertes gp100 und dessen verwendung
|
|
DE60124899T2
(de)
|
2000-05-10 |
2007-08-16 |
Sanofi Pasteur Ltd., Toronto |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
|
WO2003085087A2
(en)
*
|
2002-04-09 |
2003-10-16 |
Aventis Pasteur, Limited |
Modified cea nucleic acid and expression vectors
|
|
US8921534B2
(en)
*
|
2001-12-12 |
2014-12-30 |
Sanofi Pasteur Limited |
Enhancement of the immune response using CD36-binding domain
|
|
EP1467751A2
(de)
*
|
2002-01-17 |
2004-10-20 |
Pharmexa A/S |
Immunogenes cea
|
|
US6949629B2
(en)
*
|
2002-03-13 |
2005-09-27 |
Aspenbio, Inc. |
Methods for purifying selected CEA family member proteins
|
|
AU2003278036B2
(en)
*
|
2002-10-22 |
2009-12-10 |
Aventis Pasteur Limited |
Anti-cancer vaccines and high-dose cytokines as adjuvants
|
|
AU2004211481A1
(en)
*
|
2003-02-13 |
2004-08-26 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof
|
|
US20060286114A1
(en)
*
|
2003-08-22 |
2006-12-21 |
Luigi Aurisicchio |
Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof
|
|
KR101162970B1
(ko)
*
|
2003-10-08 |
2012-07-12 |
테리온 바이오로직스, 인크. |
변형된 ｃｅａ/ｂ7 벡터
|
|
CA2555013C
(en)
*
|
2004-02-11 |
2013-10-15 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Carcinoembryonic antigen fusions and uses thereof
|
|
CN105039266A
(zh)
|
2008-03-14 |
2015-11-11 |
赛诺菲巴斯德生物制剂有限责任公司 |
复制缺陷型黄病毒疫苗和疫苗载体
|
|
MX2013009472A
(es)
|
2011-02-15 |
2013-10-28 |
Immune Design Corp |
Metodos para mejorar respuestas inmunitarias especificas de inmunogenos por vacunas vectoriales.
|
|
SG194083A1
(en)
|
2011-04-08 |
2013-11-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
EP3388835B1
(de)
|
2012-05-16 |
2020-04-01 |
Immune Design Corp. |
Impfstoffe gegen hsv-2
|
|
WO2014140938A2
(en)
|
2013-03-14 |
2014-09-18 |
Centre Hospitalier Universitaire Vaudois |
Immunological methods
|
|
US9725494B2
(en)
*
|
2013-05-17 |
2017-08-08 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble CD27 (sCD27) and the use thereof
|
|
JP6581101B2
(ja)
|
2014-02-14 |
2019-09-25 |
イミューン デザイン コーポレイション |
局所免疫刺激及び全身免疫刺激の組み合わせによる癌の免疫療法
|
|
MX2017000630A
(es)
|
2014-07-15 |
2017-04-27 |
Immune Design Corp |
Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
|
|
WO2017120204A2
(en)
|
2016-01-05 |
2017-07-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
KR20230051601A
(ko)
|
2016-04-15 |
2023-04-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
BR112019018747A2
(pt)
|
2017-03-16 |
2020-05-05 |
Alpine Immune Sciences Inc |
proteínas imunomoduladoras variantes de cd80 e usos das mesmas
|
|
KR20190141146A
(ko)
|
2017-03-16 |
2019-12-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l2 변이체 면역조절 단백질 및 그의 용도
|
|
PL3596116T3
(pl)
|
2017-03-16 |
2024-05-13 |
Alpine Immune Sciences, Inc. |
Białka immunomodulujące wariant Pd-l1 i ich zastosowania
|
|
MX2019011026A
(es)
*
|
2017-03-17 |
2020-12-10 |
Vaximm Ag |
Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer.
|
|
EP3601367B1
(de)
|
2017-03-30 |
2024-10-09 |
The University of Queensland |
Chimäre moleküle und verwendungen davon
|
|
EP3687561A4
(de)
|
2017-09-01 |
2021-06-09 |
The Australian National University |
Immunregulatorische moleküle und deren verwendung
|
|
US11753458B2
(en)
|
2017-10-10 |
2023-09-12 |
Alpine Immune Sciences, Inc. |
CTLA-4 variant immunomodulatory proteins and uses thereof
|
|
CA3078517A1
(en)
|
2017-10-18 |
2019-04-25 |
Alpine Immune Sciences, Inc. |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
SG11202102644XA
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences Inc |
Methods and uses of variant cd80 fusion proteins and related constructs
|
|
AU2019389151A1
(en)
|
2018-11-30 |
2021-06-10 |
Alpine Immune Sciences, Inc. |
CD86 variant immunomodulatory proteins and uses thereof
|
|
WO2020214867A1
(en)
|
2019-04-17 |
2020-10-22 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant icos ligand (icosl) fusion proteins
|
|
EP4146684A2
(de)
|
2020-05-08 |
2023-03-15 |
Alpine Immune Sciences, Inc. |
April- und baff-hemmende immunmodulatorische proteine mit und ohne t-zell-hemmendes protein und verfahren zur verwendung davon
|
|
WO2022236335A1
(en)
|
2021-05-07 |
2022-11-10 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|